Elacestrant Impresses in EMERALD Trial of Breast Cancer

Pharmaceutical Business Review on LinkedIn: #orserdu #breastcancer #menarini #stemline #innovation #oncology…

Novel Selective Estrogen Receptor Degraders in Advanced Breast Cancer Use of Elacestrant in the Phase III EMERALD Trial - The ASCO Post

Updates in Management of breast cancer Highlights from ASCO ppt download

Elacestrant (Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Highlights from SABCS 2021: T-DXd, KEYNOTE-355, PADA-1 & EMERALD

J.P. Morgan 2022 Conference Review, PDF, Novartis

May 30 - June 3, 2014 Chicago, Illinois - ppt download

Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements? - ScienceDirect

ATLAS Trial of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years for Early Breast Cancer

EMERALD Trial ORSERDU™ (elacestrant) Efficacy